论文部分内容阅读
目的:探讨胃癌和癌旁组织中SIRT1的表达及其对患者预后的影响。方法:收集1990年1月至1995年12月142例胃癌单纯手术治疗患者的临床病理资料,术后生存随访资料,将癌组织与相对应癌旁组织制作组织芯片,通过免疫组化的方法,分别获得SIRT1在其中的表达评分。分析SIRT1表达与患者临床病理指标及预后之间的关系。结果:本研究最终获得113例患者的有效信息,SIRT1在113例胃癌组织中的表达显著低于癌旁组织,差异具有统计学意义(P<0.05),癌组织中SIRT1低表达患者癌体浸润深度、淋巴结转移比例、远处转移比例均显著高于高表达患者(P<0.05),pTNM分期晚期比例也高于高表达患者(P<0.05)。胃癌组织中SIRT1表达越高患者预后越好(HR=0.211,95%CI:0.124～0.360,P<0.001)。结论:胃癌组织中SIRT1表达水平与恶性表型呈负性关系,可作为预测手术治疗患者预后的生物标志物。
Objective: To investigate the expression of SIRT1 in gastric cancer and its adjacent tissues and its effect on the prognosis of patients. Methods: The clinical and pathological data of 142 patients with gastric cancer treated by surgery alone from January 1990 to December 1995 were collected. Survival follow-up data were collected. Tissue microarrays were made from cancer tissues and corresponding paracancerous tissues. By immunohistochemistry, SIRT1 was obtained in which the expression score. The relationship between SIRT1 expression and clinicopathological parameters and prognosis was analyzed. Results: The information of 113 patients was finally obtained. The expression of SIRT1 in 113 cases of gastric cancer tissues was significantly lower than that of the adjacent tissues (P <0.05). The cancer infiltration of SIRT1 in cancer tissues Depth, lymph node metastasis and distant metastasis were significantly higher than those in high expression (P <0.05). The proportion of pTNM in late stage was also higher than that in high expression (P <0.05). The higher the expression of SIRT1 in gastric cancer patients, the better the prognosis (HR = 0.211, 95% CI: 0.124 ~ 0.360, P <0.001). Conclusion: The expression of SIRT1 in gastric cancer is negatively correlated with malignant phenotype, which may be used as a biomarker to predict the prognosis of patients with surgical treatment.